{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T17:58:36Z","timestamp":1771783116934,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11253-z","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:53:09Z","timestamp":1750675989000},"page":"1271-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug repurposing for renin inhibition: identifying panobinostat for hypertension management"],"prefix":"10.1007","volume":"30","author":[{"given":"Nisha","family":"Bansal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Khalid","family":"Parvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Arockia","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed S.","family":"Al-Dosari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nemat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Bushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay M.","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"11253_CR1","volume":"8","author":"JA Arguedas","year":"2009","unstructured":"Arguedas JA, Perez MI, Wright JM (2009) Treatment blood pressure targets for hypertension. Cochrane Database of Syst Rev 8:CD004349","journal-title":"Cochrane Database of Syst Rev"},{"key":"11253_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK (2020) High blood pressure and cardiovascular disease. Hypertension 75:285\u2013292","journal-title":"Hypertension"},{"key":"11253_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics13010016","volume":"13","author":"A Martyniak","year":"2022","unstructured":"Martyniak A, Tomasik PJ (2022) A new perspective on the renin-angiotensin system. Diagnostics 13:16","journal-title":"Diagnostics"},{"key":"11253_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/CIRCRESAHA.121.318064","volume":"128","author":"MLS Sequeira-Lopez","year":"2021","unstructured":"Sequeira-Lopez MLS, Gomez RA (2021) Renin cells, the kidney, and hypertension. Circ Res 128:887\u2013907","journal-title":"Circ Res"},{"key":"11253_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41581-021-00414-6","volume":"17","author":"MC Prieto","year":"2021","unstructured":"Prieto MC, Gonzalez AA, Visniauskas B, Navar LG (2021) The evolving complexity of the collecting duct renin\u2013angiotensin system in hypertension. Nat Rev Nephrol 17:481\u2013492","journal-title":"Nat Rev Nephrol"},{"key":"11253_CR6","doi-asserted-by":"crossref","unstructured":"Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G (2020) Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019. In: Mayo Clinic Proceedings, Elsevier, pp. 1222\u20131230","DOI":"10.1016\/j.mayocp.2020.03.026"},{"key":"11253_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2021.4928","volume":"47","author":"C Su","year":"2021","unstructured":"Su C, Xue J, Ye C, Chen A (2021) Role of the central renin-angiotensin system in hypertension. Int J Mol Med 47:1\u201316","journal-title":"Int J Mol Med"},{"key":"11253_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-981-97-7380-0_5","volume-title":"Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers","author":"M Nandave","year":"2024","unstructured":"Nandave M (2024) The effect of ACE inhibitors vs. angiotensin receptor blockers on insulin resistance in hypertensive patients. In: Nandave M (ed) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers. Springer, Singapore, pp 223\u2013275"},{"key":"11253_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115466","volume":"28","author":"K Ramya","year":"2020","unstructured":"Ramya K, Suresh R, Kumar HY, Kumar BP, Murthy NS (2020) Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy A fleeting look at the old and the promising new molecules. Bioorg Med Chem 28:115466","journal-title":"Bioorg Med Chem"},{"key":"11253_CR10","volume":"2017","author":"GM Wang","year":"2020","unstructured":"Wang GM, Li LJ, Tang WL, Wright JM (2020) Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2017:CD012569","journal-title":"Cochrane Database Syst Rev"},{"key":"11253_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835","volume":"172","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Sood MM (2021) Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res 172:105835","journal-title":"Pharmacol Res"},{"key":"11253_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrneph.2011.29","volume":"7","author":"N Nobakht","year":"2011","unstructured":"Nobakht N, Kamgar M, Rastogi A, Schrier RW (2011) Limitations of angiotensin inhibition. Nat Rev Nephrol 7:356\u2013359","journal-title":"Nat Rev Nephrol"},{"key":"11253_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.112.201889","volume":"61","author":"N Moniwa","year":"2013","unstructured":"Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J (2013) Hemodynamic and hormonal changes to dual renin\u2013angiotensin system inhibition in experimental hypertension. Hypertension 61:417\u2013424","journal-title":"Hypertension"},{"key":"11253_CR14","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"H-H Parving","year":"2012","unstructured":"Parving H-H, Brenner BM, McMurray JJ, De Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204\u20132213","journal-title":"N Engl J Med"},{"key":"11253_CR15","first-page":"1","volume-title":"ACE inhibitors","author":"JR Vane","year":"2001","unstructured":"Vane JR (2001) The history of inhibitors of angiotensin converting enzyme. In: D\u2019Orl\u00e9ans-Juste P, Plante GE (eds) ACE inhibitors. Birkh\u00e4user, Basel, pp 1\u201310"},{"key":"11253_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/CS20130400","volume":"126","author":"CM Ferrario","year":"2014","unstructured":"Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell\u2019Italia LJ (2014) An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci 126:461\u2013469","journal-title":"Clin Sci"},{"key":"11253_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028501","volume":"6","author":"S Ahmad","year":"2011","unstructured":"Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM (2011) Chymase-dependent generation of angiotensin II from angiotensin-(1\u201312) in human atrial tissue. PLoS ONE 6:e28501","journal-title":"PLoS ONE"},{"key":"11253_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2165\/00003495-198400282-00003","volume":"28","author":"W Louis","year":"1984","unstructured":"Louis W, McNeil J, Drummer O (1984) Pharmacology of combined \u03b1-\u03b2-blockade I. Drugs 28:16\u201334","journal-title":"Drugs"},{"key":"11253_CR19","doi-asserted-by":"publisher","DOI":"10.1039\/d4md00720d","author":"N Bansal","year":"2025","unstructured":"Bansal N, Kathuria D, Babu AM, Dhiman S, Lakhanpal S, Prasad KN, Kumar R, Tyagi Y, Kumar B, Singh MP, Gaidhane AM (2025) A perspective on small molecules targeting the renin\u2013angiotensin\u2013aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development. RSC Med Chem. https:\/\/doi.org\/10.1039\/d4md00720d","journal-title":"RSC Med Chem"},{"key":"11253_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/0471780103","volume-title":"Drug discovery and development, volume 1: drug discovery","author":"MS Chorghade","year":"2006","unstructured":"Chorghade MS (2006) Drug discovery and development, volume 1: drug discovery. Wiley, Hoboken"},{"key":"11253_CR21","doi-asserted-by":"publisher","DOI":"10.1515\/9783110791150","volume-title":"Drug repurposing","author":"R Poduri","year":"2023","unstructured":"Poduri R, Joshi G, Sharma M, Kumar A (2023) Drug repurposing. Walter de Gruyter GmbH & Co KG, Berlin"},{"key":"11253_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1515\/9783110791150-011","volume-title":"Drug repurposing","author":"D Roy","year":"2023","unstructured":"Roy D, Rangra NK, Kumar B (2023) 11 Drug repurposing of drugs from natural and marine origins. Drug repurposing. Walter de Gruyter GmbH & Co KG, Berlin, p 221"},{"key":"11253_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"11253_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","volume":"175","author":"Y Cha","year":"2018","unstructured":"Cha Y, Erez T, Reynolds I, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E (2018) Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 175:168\u2013180","journal-title":"Br J Pharmacol"},{"key":"11253_CR25","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1039\/c2cs35357a","volume":"42","author":"D-L Ma","year":"2013","unstructured":"Ma D-L, Chan DS-H, Leung C-H (2013) Drug repositioning by structure-based virtual screening. Chem Soc Rev 42:2130\u20132141","journal-title":"Chem Soc Rev"},{"key":"11253_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fchem.2020.00343","volume":"8","author":"EHB Maia","year":"2020","unstructured":"Maia EHB, Assis LC, De Oliveira TA, Da Silva AM, Taranto AG (2020) Structure-based virtual screening: from classical to artificial intelligence. Front Chem 8:343","journal-title":"Front Chem"},{"key":"11253_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","volume":"7","author":"J Rahuel","year":"2000","unstructured":"Rahuel J, Rasetti V, Maibaum J, R\u00fceger H, G\u00f6schke R, Cohen N, Stutz S, Cumin F, Fuhrer W, Wood J (2000) Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7:493\u2013504","journal-title":"Chem Biol"},{"key":"11253_CR28","first-page":"11088","volume":"11","author":"N Muddagoni","year":"2021","unstructured":"Muddagoni N, Bathula R, Dasari M, Potlapally SR (2021) Homology modeling, virtual screening, prime-MMGBSA, AutoDock-identification of inhibitors of FGR protein. Biointerface Res Appl Chem 11:11088\u201311103","journal-title":"Biointerface Res Appl Chem"},{"key":"11253_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.141278","volume":"1328","author":"SK Baidya","year":"2025","unstructured":"Baidya SK, Patel T, Himaja A, Banerjee S, Das S, Ghosh B, Jha T, Adhikari N (2025) Synthesis, biological assessment, and in silico binding mode interaction analyses and DFT studies of biphenylsulfonamide-based potent MMP-2 inhibitors effective against chronic myeloid leukemia. J Mol Struct 1328:141278","journal-title":"J Mol Struct"},{"key":"11253_CR30","unstructured":"Drug Approvals and Databases, in, 2024"},{"key":"11253_CR31","doi-asserted-by":"crossref","unstructured":"Repasky MP, Shelley M, Friesner RA (2007) Flexible ligand docking with Glide. Curr Protocols Bioinformatics 18: 8.12. 11\u201318.12. 36","DOI":"10.1002\/0471250953.bi0812s18"},{"key":"11253_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22255","volume":"85","author":"SK Baidya","year":"2024","unstructured":"Baidya SK, Patel T, Himaja A, Banerjee S, Das S, Ghosh B, Jha T, Adhikari N (2024) Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis. Drug Dev Res 85:e22255","journal-title":"Drug Dev Res"},{"key":"11253_CR33","unstructured":"S. Maestro, LLC, New York, NY (2017)"},{"key":"11253_CR34","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZ, Hou TJCR (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119:9478\u20139508","journal-title":"Chem Rev"},{"issue":"24","key":"11253_CR35","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1080\/07391102.2023.2276315","volume":"42","author":"P Vishwakarma","year":"2023","unstructured":"Vishwakarma P, Siddiqui NF, Thakur S, Jadhav H (2023) Dynamics FDA approved fused-pyrimidines as potential PI3K inhibitors: a computational repurposing approach. J Biomol Struct Dyn 42(24):13497\u201313514","journal-title":"J Biomol Struct Dyn"},{"key":"11253_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1006\/abio.1993.1207","volume":"210","author":"GT Wang","year":"1993","unstructured":"Wang GT, Chung CC, Holzman TF, Krafft GA (1993) A continuous fluorescence assay of renin activity. Anal Biochem 210:351\u2013359","journal-title":"Anal Biochem"},{"key":"11253_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.931475","volume":"9","author":"Y Han","year":"2022","unstructured":"Han Y, Nie J, Wang DW, Ni L (2022) Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors. Front Cardiovasc Med 9:931475","journal-title":"Front Cardiovasc Med"},{"key":"11253_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s12272-020-01297-0","volume":"43","author":"P Chun","year":"2020","unstructured":"Chun P (2020) Therapeutic effects of histone deacetylase inhibitors on heart disease. Arch Pharmacal Res 43:1276\u20131296","journal-title":"Arch Pharmacal Res"},{"key":"11253_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","volume":"52","author":"S Yoon","year":"2016","unstructured":"Yoon S, Eom GH (2016) HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 52:1\u201311","journal-title":"Chonnam Med J"},{"key":"11253_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fcvm.2017.00019","volume":"4","author":"AJ Bauer","year":"2017","unstructured":"Bauer AJ, Martin KA (2017) Coordinating regulation of gene expression in cardiovascular disease: interactions between chromatin modifiers and transcription factors. Front Cardiovasc Med 4:19","journal-title":"Front Cardiovasc Med"},{"key":"11253_CR41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.33594\/000000306","volume":"54","author":"H Muzi-Filho","year":"2020","unstructured":"Muzi-Filho H, Jannuzzi LB, Bouzan AC, Alves-Barros S, Alves-Bezerra DS, Pereira-Ac\u00e1cio A, Ferreira BS, Silva-Pereira D, Costa-Sarmento G, Vieyra A (2020) Histone deacetylase activity and the renin-angiotensin-aldosterone system: key elements in cardiorenal alterations provoked by chronic malnutrition in male adult rats. Cell Physiol Biochem 54:1143\u20131162","journal-title":"Cell Physiol Biochem"},{"key":"11253_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.105.559724","volume":"113","author":"HJ Kee","year":"2006","unstructured":"Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang Y-J, Kim N (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113:51\u201359","journal-title":"Circulation"},{"key":"11253_CR43","first-page":"H1894","volume":"302","author":"T Usui","year":"2012","unstructured":"Usui T, Okada M, Mizuno W, Oda M, Ide N, Morita T, Hara Y, Yamawaki H (2012) HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats, American Journal of Physiology-Heart and Circulatory. Physiology 302:H1894\u2013H1904","journal-title":"Physiology"},{"key":"11253_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/HYPERTENSIONAHA.110.154567","volume":"56","author":"JP Cardinale","year":"2010","unstructured":"Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J (2010) HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 56:437\u2013444","journal-title":"Hypertension"},{"key":"11253_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213186","volume":"14","author":"Y Ryu","year":"2019","unstructured":"Ryu Y, Kee HJ, Sun S, Seok YM, Choi SY, Kim GR, Kee S-J, Pflieger M, Kurz T, Kim H-S (2019) Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension. PLoS ONE 14:e0213186","journal-title":"PLoS ONE"},{"key":"11253_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1203\/PDR.0b013e3181da477c","volume":"67","author":"R Song","year":"2010","unstructured":"Song R, Van Buren T, Yosypiv IV (2010) Histone deacetylases are critical regulators of the renin-angiotensin system during ureteric bud branching morphogenesis. Pediatr Res 67:573\u2013578","journal-title":"Pediatr Res"},{"key":"11253_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/ijms20010102","volume":"20","author":"J Habibian","year":"2018","unstructured":"Habibian J, Ferguson BS (2018) The crosstalk between acetylation and phosphorylation: emerging new roles for HDAC inhibitors in the heart. Int J Mol Sci 20:102","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11253-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T17:03:21Z","timestamp":1771779801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11253-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11253"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11253-z","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}